Psoriatic Disease
FDA OKs Bimzelx for psoriatic arthritis, ankylosing spondylitis, non-radiographic axSpA
The FDA has expanded the indication of Bimzelx to include psoriatic arthritis, ankylosing spondylitis and non-radiographic axial spondyloarthritis with objective signs of inflammation, according to a press release.
National Psoriasis Foundation to honor leaders at 2025 Commit to Cure Gala
The National Psoriasis Foundation has announced the honorees for this year’s Commit to Cure Gala, according to a press release.
Blue-collar workers more likely to miss work, quit due to psoriatic arthritis
Blue-collar workers with psoriatic arthritis demonstrate an increased risk for work disability vs. white-collar workers with the same disease, according to data published in Clinical Rheumatology.
Infliximab biosimilar uptake rapidly increased only after release of a third option
Infliximab biosimilar uptake increased by no more than just 5% annually following the release of its first two biosimilars, but then shot up by 13% to 16% for most patients after a third option emerged, according to data.
‘Pristine’ safety profile sets TYK2i apart from JAK ‘baggage’ in psoriatic disease, lupus
In September 2022, the FDA approved deucravacitinib for moderate-to-severe plaque psoriasis, officially introducing tyrosine kinase 2 inhibition to clinics across the United States.